Cytek Biosciences (NASDAQ:CTKB – Get Free Report) and Harvard Bioscience (NASDAQ:HBIO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Analyst Ratings
This is a summary of current ratings and target prices for Cytek Biosciences and Harvard Bioscience, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cytek Biosciences | 1 | 1 | 2 | 0 | 2.25 |
| Harvard Bioscience | 1 | 3 | 1 | 0 | 2.00 |
Cytek Biosciences presently has a consensus price target of $5.67, indicating a potential downside of 2.97%. Harvard Bioscience has a consensus price target of $6.75, indicating a potential downside of 28.12%. Given Cytek Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Cytek Biosciences is more favorable than Harvard Bioscience.
Volatility and Risk
Cytek Biosciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
Valuation and Earnings
This table compares Cytek Biosciences and Harvard Bioscience”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cytek Biosciences | $201.49 million | 3.79 | -$66.54 million | ($0.63) | -9.27 |
| Harvard Bioscience | $86.55 million | 0.50 | -$56.70 million | ($2.59) | -3.63 |
Harvard Bioscience has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cytek Biosciences and Harvard Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cytek Biosciences | -39.10% | -13.13% | -9.56% |
| Harvard Bioscience | -13.20% | -43.94% | -5.15% |
Insider and Institutional Ownership
69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Cytek Biosciences beats Harvard Bioscience on 7 of the 13 factors compared between the two stocks.
About Cytek Biosciences
Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company’s product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.
About Harvard Bioscience
Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
